Charles River Laboratories CRL · NYSE
$337.49 +7.82% (+$24.47)
Summary
32 / 100 · Bulios Score
What speaks for it
- It beat profit estimates 8 times in the last 8 quarters.
- It passes 8 of the 9 points of the Piotroski financial health test.
What to watch
- Operating profit does not even cover the interest on its debt.
- The share price is above the Bulios Fair Price.
- Out of every 100 USD of revenue, only 1.0 USD is left as net profit.
- Revenue grew by only 0.3% a year over the last 3 years.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 375.3 USD for 1 USD of yearly profit. Over the last five years it was 257.9 USD on average.
Valuation in detailIs it growing?
SlowlyRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 6.5% a year over 5 years. Over the last 3 years it grew by 0.3% a year. For the next fiscal year analysts expect revenue to fall by 2.4%.
Growth in detailDoes it make money?
ReasonablyWhere 100 USD of revenue goes
- Cost of sales 67 USD
- Sales and administration 19 USD
- Taxes and other 13 USD
- Net profit 1.0 USD
Net profit, industry median (Medical - Diagnostics & Research) 9.8 USD
Out of every 100 USD of revenue, 1.0 USD is left as net profit.
Profitability in detailIs it financially healthy?
Debt is a burdenRepaying all its debt would take 7.1 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 28
- Hold 9
- Sell 0
Today's price within the analysts' price targets
The average target of $308.36 is 8.6% below today's price. 76% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Discovery and Safety Assessment 60%
- Research Models and Services 21%
- Manufacturing Support 19%
By region
- UNITED STATES 54%
- Europe 28%
- CANADA 13%
- Asia Pacific 5.2%
Discovery and Safety Assessment brings in 60% of revenue. Research Models and Services grew fastest, by 5.2% a year.
Segments in detail